Vadim Koshkin, MD
Dr. Vadim Koshkin is a genitourinary medical oncologist at the University of California San Francisco where he leads the bladder cancer clinical program in medical oncology. He completed his medical degree at the University of Chicago Pritzker School of Medicine, internal medicine training at the University of Michigan and fellowship in medical oncology at the Cleveland Clinic, and his interests are focused in clinical and translational research of bladder and prostate cancer.
Articles by Vadim Koshkin, MD
Dr. Vadim Koshkin gives his thoughts on the CheckMate 901 study and its data that were presented at the conference.
The trio highlights the results of a study on whether bone scans overstage PC compared with PSMA PET at initial staging.
A background on PSMA PET scans for staging of prostate cancer and comparison of accuracy of conventional vs PSMA PET imaging.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
The panel discusses studies and areas of interest related to treatment options for advanced bladder cancer.
The panel discussed how treatments used in the metastatic space are moving into the perioperative setting.
The panel discusses the potential for more targeted treatments making their way into the advanced bladder cancer space.
The panel addresses treatment sequencing decisions following disease relapse.
The panel discusses the approach to treating patients with platinum-ineligible bladder cancer.
The panel discusses patient characteristics and treatment sequencing considerations.
The panel discusses the approach to treating patients with cisplatin-ineligible bladder cancer.
The panel discusses the approach to treating patients with cisplatin-eligible bladder cancer.
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.